Cargando…

Dosage Modification of Traditional Chinese Medicine Prescriptions: An Analysis of Two Randomized Controlled Trials

Traditional Chinese medicine (TCM) prescriptions lack standardization due to the complex composition of the prescribed herbs, the unclear mechanism of the formulas, and a lack of scientific data to support the dose-response relationship. Here, we proposed a new clinical strategy of dosage modificati...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Rongrong, Zheng, Yujiao, An, Xuedong, Jin, De, Lian, Fengmei, Tong, Xiaolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672220/
https://www.ncbi.nlm.nih.gov/pubmed/34925003
http://dx.doi.org/10.3389/fphar.2021.732698
_version_ 1784615314987679744
author Zhou, Rongrong
Zheng, Yujiao
An, Xuedong
Jin, De
Lian, Fengmei
Tong, Xiaolin
author_facet Zhou, Rongrong
Zheng, Yujiao
An, Xuedong
Jin, De
Lian, Fengmei
Tong, Xiaolin
author_sort Zhou, Rongrong
collection PubMed
description Traditional Chinese medicine (TCM) prescriptions lack standardization due to the complex composition of the prescribed herbs, the unclear mechanism of the formulas, and a lack of scientific data to support the dose-response relationship. Here, we proposed a new clinical strategy of dosage modification for TCM prescriptions to evaluate the clinical efficacy and guide the clinical medication. This study used two TCM prescriptions for the treatment of newly diagnosed type 2 diabetes mellitus (T2DM) to explore the key indications and the most appropriate critical values of dosage modification by analyzing two randomized controlled trials (RCTs). In this study, the indications refer to a change in the indicators from baseline at a certain time point (week 4, week 8, week 12), which could predict the change in outcome indicators, and the critical values refer to the change ranges closely related to the decrease in HbA1c at week 12. In Study 1, the correlation analysis between the change range of indicators at three time points (weeks 4, 8, and 12) from baseline and the decrease in HbA1c at week 12 from baseline (HbA1c 012) was carried out to screen the related indications. Next, we evaluate the related indications and the respective critical values to determine the key indicators, indications, and the most appropriate critical value. We conducted a correlation between the change range of key indicators (obtained from the result of Study 1) at three time points from baseline and HbA1c 012 to screen the key indications in the drug group, high-dose group, and low-dose group in Study 2. Key indications with critical values were determined to investigate the most appropriate critical value in the three groups separately. In Study 1, the key indicator was FBG, the key indication was FBG 04, and the most appropriate critical value was 0.5 mmol/L. In Study 2, the key indication was FBG 04 and the most appropriate critical value was 0.6 mmol/L in the drug group. In the high-dose group, the key indication was FBG 04, and the most appropriate critical value was 0.3 mmol/L. In the low-dose group, the key indication was FBG08, and the most appropriate critical value was 0.1 mmol/L. In addition, we summarized a verification strategy for dosage modification.
format Online
Article
Text
id pubmed-8672220
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86722202021-12-16 Dosage Modification of Traditional Chinese Medicine Prescriptions: An Analysis of Two Randomized Controlled Trials Zhou, Rongrong Zheng, Yujiao An, Xuedong Jin, De Lian, Fengmei Tong, Xiaolin Front Pharmacol Pharmacology Traditional Chinese medicine (TCM) prescriptions lack standardization due to the complex composition of the prescribed herbs, the unclear mechanism of the formulas, and a lack of scientific data to support the dose-response relationship. Here, we proposed a new clinical strategy of dosage modification for TCM prescriptions to evaluate the clinical efficacy and guide the clinical medication. This study used two TCM prescriptions for the treatment of newly diagnosed type 2 diabetes mellitus (T2DM) to explore the key indications and the most appropriate critical values of dosage modification by analyzing two randomized controlled trials (RCTs). In this study, the indications refer to a change in the indicators from baseline at a certain time point (week 4, week 8, week 12), which could predict the change in outcome indicators, and the critical values refer to the change ranges closely related to the decrease in HbA1c at week 12. In Study 1, the correlation analysis between the change range of indicators at three time points (weeks 4, 8, and 12) from baseline and the decrease in HbA1c at week 12 from baseline (HbA1c 012) was carried out to screen the related indications. Next, we evaluate the related indications and the respective critical values to determine the key indicators, indications, and the most appropriate critical value. We conducted a correlation between the change range of key indicators (obtained from the result of Study 1) at three time points from baseline and HbA1c 012 to screen the key indications in the drug group, high-dose group, and low-dose group in Study 2. Key indications with critical values were determined to investigate the most appropriate critical value in the three groups separately. In Study 1, the key indicator was FBG, the key indication was FBG 04, and the most appropriate critical value was 0.5 mmol/L. In Study 2, the key indication was FBG 04 and the most appropriate critical value was 0.6 mmol/L in the drug group. In the high-dose group, the key indication was FBG 04, and the most appropriate critical value was 0.3 mmol/L. In the low-dose group, the key indication was FBG08, and the most appropriate critical value was 0.1 mmol/L. In addition, we summarized a verification strategy for dosage modification. Frontiers Media S.A. 2021-12-01 /pmc/articles/PMC8672220/ /pubmed/34925003 http://dx.doi.org/10.3389/fphar.2021.732698 Text en Copyright © 2021 Zhou, Zheng, An, Jin, Lian and Tong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhou, Rongrong
Zheng, Yujiao
An, Xuedong
Jin, De
Lian, Fengmei
Tong, Xiaolin
Dosage Modification of Traditional Chinese Medicine Prescriptions: An Analysis of Two Randomized Controlled Trials
title Dosage Modification of Traditional Chinese Medicine Prescriptions: An Analysis of Two Randomized Controlled Trials
title_full Dosage Modification of Traditional Chinese Medicine Prescriptions: An Analysis of Two Randomized Controlled Trials
title_fullStr Dosage Modification of Traditional Chinese Medicine Prescriptions: An Analysis of Two Randomized Controlled Trials
title_full_unstemmed Dosage Modification of Traditional Chinese Medicine Prescriptions: An Analysis of Two Randomized Controlled Trials
title_short Dosage Modification of Traditional Chinese Medicine Prescriptions: An Analysis of Two Randomized Controlled Trials
title_sort dosage modification of traditional chinese medicine prescriptions: an analysis of two randomized controlled trials
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672220/
https://www.ncbi.nlm.nih.gov/pubmed/34925003
http://dx.doi.org/10.3389/fphar.2021.732698
work_keys_str_mv AT zhourongrong dosagemodificationoftraditionalchinesemedicineprescriptionsananalysisoftworandomizedcontrolledtrials
AT zhengyujiao dosagemodificationoftraditionalchinesemedicineprescriptionsananalysisoftworandomizedcontrolledtrials
AT anxuedong dosagemodificationoftraditionalchinesemedicineprescriptionsananalysisoftworandomizedcontrolledtrials
AT jinde dosagemodificationoftraditionalchinesemedicineprescriptionsananalysisoftworandomizedcontrolledtrials
AT lianfengmei dosagemodificationoftraditionalchinesemedicineprescriptionsananalysisoftworandomizedcontrolledtrials
AT tongxiaolin dosagemodificationoftraditionalchinesemedicineprescriptionsananalysisoftworandomizedcontrolledtrials